CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies-Reference-Cited by-同舟云学术

CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies

Published:2021-06 Issue:16 Volume:17 Page:2107-2122
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Harbeck Nadia¹^ORCID,Bartlett Meaghan²^ORCID,Spurden Dean³^ORCID,Hooper Becky²^ORCID,Zhan Lin³,Rosta Emily²,Cameron Chris²^ORCID,Mitra Debanjali³^ORCID,Zhou Anna²^ORCID

Affiliation:

1. Breast Center, Department of Gynecology & Obstetrics & Comprehensive Cancer Center, LMU University Hospital, Munich, 81377, Germany

2. CRG-EVERSANA Canada, Inc., Burlington, ON L7N 3H8, Canada

3. Pfizer, Inc., NY 10017, USA

Abstract

Background: This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods: A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results: This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and demonstrated improved outcomes. There are limited long-term and comparative data between CDK4/6i and endocrine monotherapy, and within the CDK4/6i class. Conclusion: Available RWE suggests that CDK4/6i are associated with improved outcomes in HR+/HER2- a/mBC, although additional studies with longer follow-up periods are needed.

Funder

Pfizer

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-1264

Reference79 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. International Agency for Research on Cancer. Breast fact sheet. (2020). https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf

3. International Agency for Research on Cancer. Very high HDI fact sheet. (2020). https://gco.iarc.fr/today/data/factsheets/populations/981-very-high-hdi-fact-sheets.pdf

4. 1st International consensus guidelines for advanced breast cancer (ABC 1)

5. Extending Survival with Chemotherapy in Metastatic Breast Cancer

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

2. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23

3. Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia;Journal of Personalized Medicine;2024-08-23

4. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand;BMC Cancer;2024-08-16

5. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS);Expert Opinion on Drug Safety;2024-08-05